ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

ClearPoint Neuro, Inc.

Our mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of our current product portfolio include deep-brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics and gene therapy to the brain. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in 60+ Clinical & Research Centers in the US, Canada, & EU... and growing globally. ClearPoint Neuro’s SmartFlow® cannula is being used in partnership or evaluation with 30+ individual biologics and drug delivery companies in various stages, from preclinical research to late stage regulatory trials. To date, more than 4,000 cases have been performed and supported by our field-based Clinical Specialist team which offers support and services for our partners.

Hear the remarkable story of 3-year-old AADC Deficiency patient Simone. In May, he underwent the first commercial brain gene therapy procedure in Italy using ClearPoint’s SmartFlow cannula with our MRI-guided navigation platform. #CLPT #AADCdefiency #GeneTherapy #Nsgy #SmartFlow - https://loom.ly/rIn9EQE

To wrap up #WorldQualityWeek we're delighted to celebrate our amazing #Quality team. Since 2021 they have completed 15 successful audits, achieved MDSAP certification, Anvisa approval of our portfolio in Brazil, as well as approval by the State of California for our new Carlsbad manufacturing facility. #CLPT

ClearPoint Neuro reports Third Quarter 2023 results -  Biologics & Drug Delivery growing 55%; Q3 operational cash burn of $1.8M #CLPT
 bit.ly/3SzHjVF

Thanks to everyone who attended Lyubomir Zagorchev, PhD's  presentation yesterday & reach out if you’d like to learn more about our solutions for segmentation of subcortical structures and infusion coverage analysis. We look forward to another day of sessions at the Hanson Wade Group Gene Therapy for Neurological Disorders conference. #CLPT

Are you attending the Hanson Wade Group Gene Therapy for Neuro conference in Boston starting tomorrow? Join us to hear Lyubomir Zagorchev, PhD present on Analysis of Intraparenchymal Delivery in Clinical Trials and Preclinical Studies, and stop by our exhibit table to meet with the ClearPoint team! #CLPT

We are honored the ClearPoint #Prism Neuro Laser Therapy System is included at this weekend’s #ASSFN Neurosurgical Stereotactic & Functional Hands-On course at the University of Colorado Anschutz Medical Campus. Residents & fellows will learn the #ClearPoint workflow for laser and #DBS from our Director of Education & Training, Kara Kittelberger, PhD. Thanks to Daniel Schoenecker & Kara for supporting this course! #Nsgy #MedicalEducation #CLPT

#ClearPoint is proud to have supported 1660+ cases so far guiding #LaserTherapy, #DBS, & #DrugDelivery in #ClinicalTrials to treat drug-resistant #Epilepsy. With our ClearPoint #Prism Neuro Laser Therapy System, we’re delighted to offer our 1st therapeutic device to help epilepsy patients. #NEAM2023 #EpilepsyAwareness #Nsgy #CLPT

For October’s employee highlight, we’ve chosen to celebrate #Production Manager, Sean Nakaoka! We’re grateful to have such a knowledgeable and dedicated manager supporting our Carlsbad-based #Operations on the #ClearPoint team. #ProductionManager #Manufacturing #EmployeeHighlight #CLPT

ClearPoint Neuro to announce Third Quarter 2023 results November 9, 2023 after market close. https://lnkd.in/giBdxBa4 #CLPT bit.ly/3FwbXHW

Thanks to everyone who stopped by our #ESGCT2023 posters last night, and we look forward to another session tonight. Find us at Booth 38 if you’re at the conference, or reach out if you’d like to receive a digital copy of any of the #ClearPoint posters.
#CellTherapy #GeneTherapy #CLPT

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	3.93M -	3.60M 8.30%	4.59M 27.46%	5.75M 25.15%	7.38M 28.35%	7.35M 0.36%	11.22M 52.54%	12.83M 14.37%	16.30M 27.05%	20.55M 26.09%	23.95M 16.56%
cost of revenue	1.42M -	1.93M 35.60%	1.99M 3.14%	2.64M 32.96%	2.90M 9.69%	2.43M 16.07%	3.83M 57.53%	3.71M 3.23%	5.01M 35.02%	7.02M 40.18%	10.34M 47.31%
gross profit	2.51M -	1.68M 33.16%	2.61M 55.40%	3.11M 19.19%	4.48M 44.23%	4.92M 9.81%	7.38M 50.08%	9.12M 23.51%	11.29M 23.80%	13.53M 19.84%	13.61M 0.61%
selling and marketing expenses					3.96M -	3.53M 10.73%	4.76M 34.64%	5.38M 13.22%	6.92M 28.51%	9.36M 35.25%	12.60M 34.59%
general and administrative expenses					4.05M -	4.33M 6.91%	4.30M 0.60%	5.27M 22.56%	8.76M 66.24%	9.61M 9.70%	11.76M 22.32%
selling general and administrative expenses	7.06M -	8.04M 13.85%	8.37M 4.12%	7.97M 4.82%	8.00M 0.45%	7.86M 1.81%	9.06M 15.24%	10.65M 17.65%	15.68M 47.17%	18.97M 20.98%	24.35M 28.37%
research and development expenses	2.92M -	3.30M 12.80%	1.96M 40.63%	2.63M 34.27%	2.81M 7.06%	2.31M 17.90%	2.92M 26.50%	4.69M 60.35%	8.98M 91.74%	10.89M 21.25%	11.71M 7.48%
other expenses	863.79K -	1.80M 108.74%	230.88K 87.20%	216.07K 6.41%	16.68K 92.28%	364 97.82%	9.05K 2,387.36%	882K 9,641.55%	-63K 107.14%	-22K 65.08%	-29K 31.82%
cost and expenses	11.41M -	13.26M 16.29%	12.32M 7.15%	13.24M 7.49%	13.72M 3.60%	12.60M 8.12%	15.81M 25.47%	19.05M 20.48%	29.67M 55.77%	36.88M 24.30%	46.40M 25.81%
operating expenses	9.98M -	11.34M 13.55%	10.33M 8.90%	10.60M 2.59%	10.82M 2.09%	10.17M 6.00%	11.98M 17.80%	15.34M 28.07%	24.66M 60.79%	29.86M 21.07%	36.06M 20.75%
interest expense	475.30K -	1.01M 111.91%	1.26M 25.33%	1.06M 16.02%	872.93K 17.65%	980.38K 12.31%	955.17K 2.57%	1.44M 51.18%	973K 32.62%	81K 91.68%	386K 376.54%
ebitda	-6.61M -	-7.86M 18.83%	-7.26M 7.56%	-7.11M 2.12%	-6.20M 12.74%	-5.14M 17.17%	-4.33M 15.65%	-4.79M 10.40%	-12.74M 166.35%	-15.58M 22.22%	-20.99M 34.74%
operating income	-7.47M -	-5.32M 28.82%	-8.97M 68.67%	-7.49M 16.55%	-6.34M 15.40%	-5.25M 17.17%	-4.59M 12.46%	-6.22M 35.40%	-13.37M 115.02%	-16.33M 22.12%	-22.45M 37.44%
depreciation and amortization	426.18K -	377.26K 11.48%	211.95K 43.82%	155.71K 26.53%	116.45K 25.21%	109.44K 6.02%	259.61K 137.22%	1.44M 452.74%	629K 56.17%	755K 20.03%	1.46M 92.98%
total other income expenses net	863.79K -	6.14M 611.01%	518.17K 91.56%	470.10K 9.28%	41.41K 91.19%	64.68K 56.20%	-946.11K 1,562.71%	-562K 40.60%	-1.04M 84.34%	-103K 90.06%	357K 446.60%
income before tax	-7.09M -	-4.52M 36.15%	-8.45M 86.73%	-8.07M 4.49%	-7.17M 11.18%	-6.16M 14.01%	-5.54M 10.12%	-6.78M 22.42%	-14.41M 112.47%	-16.43M 14.05%	-22.09M 34.40%
income tax expense	912.90K -	2.43M 166.51%	1.49M 38.63%	1.28M 14.54%	889.61K 30.29%	64.68K 92.73%	964.22K 1,390.71%	2.33M 141.23%	910K 60.88%	103K 88.68%
net income	-7.09M -	-4.52M 36.15%	-8.45M 86.73%	-8.07M 4.49%	-7.17M 11.18%	-6.16M 14.01%	-6.50M 5.53%	-9.11M 40.04%	-15.32M 68.20%	-16.54M 7.95%	-22.09M 33.57%
weighted average shs out	1.43M -	1.48M 3.46%	1.88M 27.27%	2.75M 46.16%	7.74M 180.90%	10.93M 41.22%	13.16M 20.38%	15.85M 20.48%	20.73M 30.82%	24.18M 16.63%	24.61M 1.75%
weighted average shs out dil	1.43M -	1.48M 3.46%	1.88M 27.27%	2.75M 46.16%	7.74M 180.90%	10.93M 41.22%	13.16M 20.38%	15.85M 20.48%	20.73M 30.82%	24.18M 16.63%	24.61M 1.75%
eps	-4.95 -	-3.06 38.18%	-4.48 46.41%	-2.93 34.60%	-0.93 68.26%	-0.56 39.78%	-0.49 12.50%	-0.57 16.33%	-0.74 29.82%	-0.68 8.11%	-0.90 32.35%
epsdiluted	-4.95 -	-3.06 38.18%	-4.48 46.41%	-2.93 34.60%	-0.93 68.26%	-0.56 39.78%	-0.49 12.50%	-0.57 16.33%	-0.74 29.82%	-0.68 8.11%	-0.90 32.35%

COM:CLEARPOINTNEURO

ClearPoint Neuro

Last Close

11.09

22/11 21:00

Market Cap

198.25M

Beta: -

Volume Today

327.16K

Avg: -

Preview